Editas Medicine, Inc. (EDIT) vs Prothena Corporation plc (PRTA)
A side-by-side comparison of Editas Medicine, Inc. and Prothena Corporation plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EDIT
Editas Medicine, Inc.
$2.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PRTA
Prothena Corporation plc
$8.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EDIT vs PRTA
growth of $100 · dividends reinvested · last 10yEDIT -81.4% (-15.5%/yr)PRTA -86.6% (-18.2%/yr)EDIT compounded faster over this window
EDIT PRTA
EDIT vs PRTA: by the numbers
- •PRTA is the larger company ($420M vs $419M market cap).
- •Both run net losses; PRTA's is the smaller (-80.67% vs -157.32% net margin).
- •PRTA grew revenue faster over the past five years (62.57% vs -10.34% CAGR).
Metrics side by side
Valuation
| Metric | EDIT | PRTA |
|---|---|---|
| Forward P/E | N/A | 72.91 |
| P/S ratio | 8.91 | 7.70 |
| P/B ratio | 3.98 | 1.46 |
Profitability
| Metric | EDIT | PRTA |
|---|---|---|
| Gross margin | 100.00% | 61.77% |
| Operating margin | -245.15% | -1905.82% |
| Net margin | -157.32% | -80.67% |
| ROE | -70.24% | -15.33% |
| ROIC | -48.61% | -21.36% |
Growth (annualized)
| Metric | EDIT | PRTA |
|---|---|---|
| Revenue CAGR (5Y) | -10.34% | 62.57% |
| Total return CAGR (5Y) | -40.76% | -35.08% |
Frequently asked
- Which has grown faster, EDIT or PRTA?
- Over the past five years, PRTA grew revenue faster — EDIT at a -10.34% CAGR versus PRTA at 62.57%.
- How have EDIT and PRTA total returns compared?
- Over the past 10 years, EDIT delivered -15.75% and PRTA delivered -18.37% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Editas Medicine ROEProthena ROEEditas Medicine operating marginProthena operating marginEditas Medicine revenue growthProthena revenue growthEditas Medicine free cash flowProthena free cash flow
Editas Medicine & Prothena appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.